Cell Medica Ltd has further extended its global footprint with the opening of a manufacturing facility in Germany which will support the commercial launch of its lead cell product for the prevention and treatment of cytomegalovirus infections.
The boundaries of stem-cell technology have once again pushed back with a finding by Spanish researchers that adult mouse cells can be reprogrammed in vivo to generate induced pluripotent stem (iPS) cells. The finding was reported on 11 September, 2013 in Nature.
Evotec AG, the Hamburg-based drug discovery and development company, has once again joined forces with scientists at Harvard University – this time to identify compounds that could prevent or slow down the loss of motor neurons in disease.
Kiadis Pharma BV of the Netherlands has disclosed five-year follow-up data for an allogeneic stem cell treatment for patients undergoing transplantations for leukaemia which showed a survival rate of 67% at the optimal dose. The data has been submitted to a peer-reviewed medical journal for publication.
TiGenix NV, the Belgian developer of cell therapies, reported a 7.5% increase in sales to €2.3 million in the first half as it continued to roll out the cell therapy, ChondroCelect. In response to an auditor's note, it announced plans to raise working capital.
Results from an animal study suggest that endothelial precursor cells could play a role in minimising initial brain injury from a stroke and help repair stroke damage, according to an article in the August issue of STEM CELLS Translational Medicine.
The Belgian university, KU Leuven, has joined forces with a small company in Finland to develop new immunotherapies using a proprietary gene expression technology. The Finnish partner is FIT Biotech of Tampere.
Cellular Dynamics International Inc, which is a producer of induced pluripotent stem cells (iPSCs), has priced its previously-announced initial public offering of shares at $12 per share. The shares will begin trading today on Nasdaq.
The ReNeuron Group Plc has secured new funding commitments of £33 million, enabling it to advance its three allogeneic stem cell programmes through Phase 2 development. The funding includes a large grant from the Welsh government.
TiGenix NV has raised €6.5 million in a private placement of its shares to finance the continued roll-out of its cell therapy for knee injuries ChondroCelect. A total of 26 million new shares were placed via an accelerated bookbuilding procedure.